Product Description
Mechanisms of Action: TOP1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: European Medicines Agency
Approved Indications: None
Known Adverse Events: None
Company: Nektar
Company Location: SAN FRANCISCO CA 94158
Company CEO: Howard W. Robin
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Breast Cancer|Brain Cancer
Phase 2: Colorectal Cancer|Astrocytoma|Breast Cancer|Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer|Brain Cancer|Oligodendroglioma|Glioblastoma|Cervical Cancer|Ovarian Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016-002453-38 | P3 |
Completed |
Brain Cancer|Breast Cancer |
2020-07-21 |
|
| ATTAIN | P3 |
Completed |
Breast Cancer |
2020-07-01 |
|
| IRB-30982 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Breast Cancer|Brain Cancer |
2018-09-08 |
|
| 11-PIR-09 | P2 |
Completed |
Oncology Solid Tumor Unspecified |
2017-08-01 |